IP Library › Patent Application 16507424
Patent Application
App. No. 16/507,424

MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/507,424
Abstract

The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.

Claims (3)

10 - 15 . (canceled)

16 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and mazindol.

17 . The composition of claim 16 , further comprising iron or a pharmaceutically acceptable salt thereof and/or a psychostimulant.

Assignments (1)
CHANGE OF NAME Recorded Sep 12, 2019
From: NLS-1 PHARMA AG
To: NLS PHARMACEUTICS AG
Reel/Frame 050352/0339 →